Inhaled Bevacizumab: A case study for delivery to the lung

Bevacizumab is a monoclonal antibody VEGF-inhibitor approved for treatment of cancers, including lung and colon. The goal of this study was to perform a real-time stability study of spray-dried bevacizumab dry powder formulation out to 24 months. 

Download the poster, presented at RDD Europe 2023, to learn more.

Latest content

Latest briefing from the Knowledge Center